富士胶片Avigan最快明年1月成为世界首例抗埃博拉病毒新药

富士胶片Avigan最快明年1月成为世界首例抗埃博拉病毒新药

                               
登录/注册后可看大图

  

                               
登录/注册后可看大图

发布日期：2014-11-12  来源：ibtimes  

日本富士胶片公司Fujifilm11月11日在其中期经营计划发布会上公布消息称，其分公司所开发的应对埃博拉病毒的新药“Avigan”(通用名Favipiravir)最快将会在2015年1月，成为获国际认证的埃博拉出血热治疗药物，这也将是世界首例。

                               
登录/注册后可看大图

　　据悉，新药“Avigan”已提供给欧洲部分国家抗疫，法国一位感染埃博拉病毒的女护士服用 Avigan 之后，于9月19日痊愈。
　　此外，西班牙一名染病护士也在服用 Avigan并接受合并血清等疗法后于10月19日被证实身上已无病毒。虽然已有两人用药后证实有效，但由于在医院治疗时同时使用了多种疗法，必须进一步临床试验以确定Avigan单一药物的疗效。据悉，相关研究团队将于11月中旬于几内亚先进行50人的临床试验，最早在2014年12月末就可得到初步结果。富士胶片公司表示，由于疫情紧急，将会在1个月左右的时间内完成对该药物安全性及有效性的审查。

      Fujifilm曾是全球最大的摄影胶卷生产商之一，该公司目前在扩张制药业务。2008年该公司收购了Toyama Chemical，后者的流感药品Avigan被用于对抗埃博拉。

                               
登录/注册后可看大图

Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza dru in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo on Oct. 22, 2014. Reuters/Issei Kato
Fujifilm Says Influenza Drug Avigan Has Successfully Treated Four Ebola Patients

Fujifilm Holdings Corp said Tuesday that it expects its drug Avigan, used to treat influenza, to be highly effective in treating the deadly Ebola virus, which has killed nearly 5,000 people so far. The company, which was once one of the world’s largest manufacturers of photography film, entered the pharmaceuticals business by purchasing Toyama Chemical Co in 2008.

"So far, four Ebola patients have recovered after being treated with the drug," Shigetaka Komori, Fujifilm's chairman and CEO, said, in a news conference, according to Reuters, adding: "We believe that the drug will become highly effective to treat the disease."

The company is also reportedly in talks with the U.S. Food and Drug Administration to use the drug, also known as favipiravir or T-705, on Ebola patients. Avigan, which comes in the form of a 200-miligram tablet, was approved by Japan’s Ministry of Health to be used as an anti-influenza drug in March.

The Tokyo-based company has reportedly been trying to expand its presence in the pharmaceuticals business through its subsidiary Toyama, which makes Avigan. When Fujifilm acquired Toyama, the latter's influenza drugs were still in an experimental phase.

Fujifilm, which released its targets for the 2016 financial year on Tuesday, said that it plans to have an operating profit of 220 billion yen ($1.9 billion) in 2016-17, along with 440 billion yen ($3.82 billion) in revenues from its health care business, Reuters reported.

The company’s shares climbed 3.19 percent on Tuesday, after the announcements, on the Tokyo Stock Exchange.

还第一次听说，孤陋寡闻了

好好学习天天向上